Delivery Order SPE2DB22D2211-SPE2DB25FRSPH

Award Date 3/4/25
Potential Completion Date 3/5/25
Potential Value $24K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,521.83, is for the delivery of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product. The contract type is Delivery Order with a Firm Fixed Price pricing structure, and the ultimate completion date is November 6, 2024. This award is associated with a larger Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order valued at $17,875.98, with a firm fixed-price pricing type and a completion date of February 10, 2025. The contract is for the provision of 4567202672 DUPIXENT 300 MG/2 ML SYRINGE 2ML, a prescription medication. The award is part of a larger Indefinite Delivery Contract (IDC) that...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, with a ceiling value of $1,709.46, is for the delivery of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product. The contract is a Delivery Order placed under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,914.10 firm fixed-price delivery order is for the supply of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product. The award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026....
This federal contract award, valued at $33,475.18, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product, with a completion date of June 13, 2024. The contract is a delivery order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract, valued at up to $12,642.36, is for the delivery of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product, with a completion date of September 17, 2024. This contract is a delivery order under a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical,...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $12,640.36, is for the delivery of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product. The contract is a delivery order, with a firm fixed price pricing type, and a performance period through November 29, 2023. It is not designated as a set-aside contract. AmerisourceBergen holds...
This federal contract award, valued at $6,609.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a pharmaceutical product. The award is associated with a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,074.78 Firm Fixed Price Delivery Order contract is for the provision of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued at $999,999,999 and...
This is a $27,323.63 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award is under an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs,...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB25FRSPH
    Delivery Order

This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $23,867.16, is for the delivery of DUPIXENT 300 MG/2 ML SYRINGE 2ML, a specialty pharmaceutical product.

The award is a Delivery Order under an Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition.

Generated 6/3/25, 9:44 AM